IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
IOTA Pharmaceuticals
May 23, 2018

IOTA Pharmaceuticals announce the creation of a Glioblastoma Drug Bank to support and accelerate new research into brain cancer therapy

IOTA Pharmaceuticals Ltd (Cambridge, UK) today announced the creation of a new resource, the Glioblastoma (GBM) Drug Bank, to accelerate drug discovery research in brain cancer, especially glioblastoma. Creation of the GBM Drug Bank has been made possible by funds received from The Brain Tumour Charity, based in the UK, and is part of the Dutch-British WINDOW Consortium for glioblastoma drug discovery.

The purpose of the GBM Drug Bank is to accelerate international scientific research into glioblastoma by assembling annotated sets of approved drugs and exploratory compounds to support testing in preclinical glioblastoma studies.

Dr David Bailey, leader of IOTA's glioblastoma drug discovery program, comments “Glioblastoma is a particularly intransigent cancer for which new treatments are urgently needed. The WINDOW approach is to explore multiple avenues of attacking the disease using drugs and drug combinations. As part of the WINDOW initiative, IOTA is assembling annotated drug panels that can be used, either on their own or within specific therapy combinations, as a resource for glioblastoma researchers worldwide."

Dr David Jenkinson, Chief Scientific Officer of The Brain Tumour Charity (UK), commented: “The GBM Drug Bank is the first deliverable from the WINDOW programme, underpinning the establishment of an integrated preclinical drug discovery platform for glioblastoma.”

Glioblastoma is the most common and aggressive form of brain cancer. Each year, around 3,200 patients are diagnosed with this disease in the UK and the Netherlands. Despite improving knowledge of its genetic causes, it remains stubbornly incurable, with current treatment regimens resulting in an average survival of 12 months from diagnosis. Part of the poor prognosis of glioblastoma is due to tumour heterogeneity: different parts of the tumour have different characteristics and will respond differently to therapy. As a result, treatments may kill some of the tumour cells, but these cells are quickly replaced by treatment resistant tumour cell populations that continue to grow.

The GBM Drug Bank is designed to expedite research into drugs which already show promise in preclinical studies of glioblastoma, including 132 FDA approved drugs. IOTA is releasing both the annotated Drug Bank, and drug panels based on the GBM Drug Bank, to researchers on a world-wide basis to accelerate glioblastoma research. To learn more about the GBM Drug Bank, please visit

Notes to Editors

IOTA Pharmaceuticals Ltd

IOTA Pharmaceuticals Ltd is a specialist drug discovery and development company based in Cambridge (UK). IOTA works in partnership with leading academic and pharmaceutical company scientists to accelerate drug discovery and drug development projects. IOTA's role within the WINDOW Consortium is to design new drugs for glioblastoma using data generated by the Consortium, and to collate and disseminate the findings and resources of the WINDOW project as widely as possible, thereby promoting the global development of new drugs and drug combinations for this aggressive and intransigent cancer. For further information about IOTA, visit:


The GBM Drug Bank comprises the first set of tools produced by the BTC-funded WINDOW Consortium. The WINDOW Consortium is co-ordinated by Professor Tom Wurdinger and Dr Bart Westerman from the Department of Neuro-Oncology, VUmc Cancer Center, Amsterdam, and involves research teams at the Institute of Cancer and Genomic Sciences, Birmingham University, UK, as well as the Wellcome Trust Sanger Institute and IOTA Pharmaceuticals in Cambridge, UK. Further information on the WINDOW Consortium can be found at

The Brain Tumour Charity

The Brain Tumour Charity, based in the UK, is at the forefront of the fight to defeat brain tumours, making a difference every day to the lives of people with a brain tumour and their families. It funds pioneering research to increase survival, raises awareness of the symptoms and effects of brain tumours, and provides support for everyone affected. Find out more about the Brain Tumour Charity at: